A select group of small cap stocks will join Proactive’s Christine Corrado at the digital financial news organization’s upcoming virtual investor conference on Tuesday, July 21 at 1pm EST.
The Virtual One2One event is an online variant of the popular conference format the media company has run for over a decade and enables communication between interested investors and some of North America’s most innovative businesses.
Joining Proactive this time out are environmental engineering company BioLargo Inc (OTCQB: BLGO); VolitionRx Limited (NYSEAMERICAN:VNRX), a life sciences group, and digital media platform Bright Mountain Media (OTCQB:BMTM).
READ: BioLargo says subsidiary manufactures first AEC prototype to eliminate PFAS contaminants from water
Westminster, California-based BioLargo develops innovative products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds, and advanced wound care through a network of subsidiaries.
One subsidiary, BioLargo Engineering, Science & Technologies recently completed manufacturing on a first prototype unit of its patented BioLargo AEC (Aqueous Electrostatic Concentrator), that helps to effectively and affordably eliminate per-fluoroalkyl and poly-fluoroalkyl substances (PFAS) as contaminants from water.
“Our prototype is now ready for commercial trials, which is a big deal,” BioLargo CEO Dennis Calvert told Proactive in a recent interview.
“The next step is to take that prototype and get it in the field with customers to prove out the metrics – basically, the economics and performance value – that will set the stage for a commercial launch.”
The company is also working on a personal protection spray designed for face masks called Clyraguard.
VolitionRx is an epigenetics company that develops easy-to-use blood-based cancer tests to accurately diagnose a range of cancers founded in 2010 by Cameron Reynolds, who is its current CEO.
The firm’s NuQ platform looks for molecular signatures of cancer by focusing on the nucleosomes – a section of DNA wrapped around a core of proteins – in the blood.
However, the biotech group’s work in developing a coronavirus (COVID-19) triage test is grabbing the headlines lately. VolitionRx recently revealed promising results from two proof-of-concept clinical studies of the triage test using Nu.Q to predict the likelihood that a positive individual will develop complications and severe disease.
"Nu.Q has shown correlation with more severe COVID-19 cases implying strong prognostic potential, and we are now focused on the completion of larger longitudinal studies that would be needed to support a potential COVID-19 product launch,” CEO Reynolds told investors in a recent statement.
“If we continue to see positive results in these longitudinal studies, we aim to have a CE-marked product available on multiple platforms in 2020 and will look to launch a low-cost product that could be used in any laboratory worldwide as soon as possible thereafter.”
Bright Mountain Media is a holding company for valuable digital media properties and website titles around the world. The Boca Raton, FL-based firm owns Oceanside, a specialized video advertising services provider; MediaHouse, a data-driven technology to syndicate and monetize personalized video content; and Wild Sky Media, an interactive media company primarily geared towards a female audience with a 360 million-strong global reach.
COO Greg Peters joined Proactive earlier this month to talk about how the firm leverages its media properties to connect brands with targeted consumer demographics.
“Over the years, we’ve developed very specific, data-driven targeting,” Peters told Proactive. “It starts with (understanding) the demographic going to our websites. We take that demographic, look at its value to certain brands, and target the ad agencies or companies that we know will value that audience.”
Bright Mountain is hoping to uplist to the NYSE American exchange as it continues on the acquisition trail for new media titles.
To register for the July 21 event, please click here.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas